HERON THERAPEUTICS, INC. /DE/ (HRTX)

↓ Download CSV

CIK 0000818033 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, HERON THERAPEUTICS, INC. /DE/ reported revenue of $154.90M, up 7.4% from the prior year. The company ran a net loss, with a net margin of -13.0% and a gross margin of 73.3%. It held $255.88M in total assets against $241.54M in total liabilities.

Key ratios (FY2025)

73.3%
Gross margin
-1.6%
Operating margin
-13.0%
Net margin
-140.9%
Return on equity
+7.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$154.90M$144.28M$127.04M$107.67M$86.35M$88.64M$145.97M$77.47M$30.77M$1.28M
Cost of Revenue$41.35M$38.65M$65.11M$54.87M$46.02M$36.19M$61.62M$27.51M$4.59M$35.0K
Gross Profit$113.56M$105.64M$61.94M$52.80M
Operating Income-$2.54M-$11.53M-$110.61M-$174.66M-$217.83M-$228.16M-$210.69M-$183.94M-$194.56M-$170.91M
Net Income-$20.20M-$13.58M-$110.56M-$182.02M-$220.68M-$227.28M-$204.75M-$178.84M-$197.48M-$173.14M
EPS (Diluted)$-0.12$-0.09$-0.80$-1.67$-2.24
Total Assets$255.88M$233.15M$222.51M$250.95M$305.71M$353.56M$512.78M$462.18M$234.31M$67.48M
Total Liabilities$241.54M$266.80M$256.48M$237.38M$228.14M$117.06M$108.95M$92.02M$103.17M$88.73M
Shareholders' Equity$14.33M-$33.65M-$33.97M$13.57M$77.57M$236.49M$403.83M$370.16M$131.14M-$21.25M
Cash & Equivalents$28.65M$25.80M$28.68M$15.36M$90.54M$105.14M$71.90M$31.84M$144.58M$13.41M
Operating Cash Flow-$27.59M-$22.53M-$58.79M-$146.91M-$203.35M-$184.82M-$124.58M-$191.81M-$170.30M-$134.10M
Capital Expenditures$317.0K$1.71M$1.54M$1.82M$3.02M$6.81M$7.15M$9.17M$2.55M$3.13M
Shares Outstanding188.31M152.13M150.29M119.15M102.00M91.31M90.30M78.17M64.61M39.4K